Bupa Finance half-year profit rises 12% as customer growth strengthens capital

Bupa Finance has reported a strong set of unaudited results for the six months to 30 June 2026, supported by customer growth, price increases and improved insurance profitability.

Revenue rose 10% at constant exchange rates to £9.9 billion, while underlying profit increased 20% to £683 million. Statutory profit before tax was £654 million, up 12% at actual exchange rates.

The results matter primarily to bondholders and other creditors rather than ordinary shareholders. Bupa is ultimately owned by The British United Provident Association Limited, a company limited by guarantee with no shareholders. Its profits can therefore be reinvested in the healthcare business.

Investors can read the original company announcement or visit the Bupa Finance PLC company page for further coverage.

Bupa Finance's key half-year figures

Metric	HY 2026	HY 2025 comparison	Change
Customers	65.2 million	58.9 million	11%
Revenue	£9.9 billion	£9.0 billion at CER	10%
Underlying profit	£683 million	£571 million at CER	20%
Statutory profit before tax	£654 million	£582 million at AER	12%
Operating cash generation	£863 million	£974 million	-11%
Solvency II coverage ratio	189%	182%	7 percentage points
Leverage excluding leases	14.9%	16.4%	1.5 percentage points lower
Insurance combined operating ratio	94%	95%	1 percentage point better

CER means constant exchange rates, which removes currency movements to provide a clearer comparison of underlying trading. AER means actual exchange rates, reflecting the currencies used in the reported accounts.

Customer growth is feeding through to profit

Bupa's insurance customer base increased by 12% to 49.7 million, while the number of health provision customers rose 8% to 15.5 million. Aged care closing occupancy remained high at 94%.

That combination of more customers and price increases lifted revenue across the group. Importantly, underlying profit grew twice as quickly as revenue at constant exchange rates, suggesting Bupa achieved some operational leverage as the business expanded.

Insurance performance also improved. Bupa's combined operating ratio, or COR, fell from 95% to 94%. This measures insurance claims and operating expenses as a proportion of insurance revenue, so a lower percentage is generally better.

The insurance service result increased to £437 million from £328 million. UK-based Bupa Insurance Limited's COR remained stable at 97%, while Australia Health Insurance and Sanitas Seguros in Spain both reported improvements.

Growth was broad across Bupa's regions

All three main market units delivered higher revenue and underlying profit at constant exchange rates.

Market unit	Revenue	Revenue growth	Underlying profit	Profit growth
Bupa Asia Pacific	£3.4 billion	5%	£268 million	5%
Europe and Latin America	£3.4 billion	14%	£262 million	28%
Bupa Global, India and UK	£3.1 billion	11%	£154 million	26%

Europe and Latin America delivered the fastest profit growth, helped by customer growth, pricing and improved margins. The Bupa Global, India and UK division also performed well, with growth from insurance and higher health provision volumes.

Within the UK, insurance revenue and underlying profit increased as higher volumes and an improved loss ratio outweighed lower investment income. UK Care Services also benefited from occupancy rising to 92% from 90%.

UK Health Services grew revenue following higher customer volumes and the acquisitions of King Edward VII Hospital and New Victoria Hospital. However, its underlying profit declined as Bupa invested in those businesses to support future growth.

Capital strength is the standout for creditors

For bondholders, the 189% Solvency II coverage ratio is one of the most important figures in the announcement.

Solvency II compares the capital available to an insurer with the regulatory capital it is required to hold. Bupa's ratio rose from 182% and sits above its working range of 140% to 170%.

Own funds increased 17% to £6.8 billion, compared with a solvency capital requirement of £3.6 billion. Bupa said its position was supported by the short-duration profile of its insurance liabilities.

Leverage also moved in the right direction. Excluding lease liabilities, it fell to 14.9% from 16.4%. Including leases, leverage declined to 22.4% from 23.7%.

The group's £900 million revolving credit facility remained undrawn at the end of June, with strong covenant coverage. There were no credit rating movements during the half year.

These figures point to a substantial capital cushion and continued access to liquidity, both of which are supportive for creditors.

Cash flow was lower despite higher profit

The main soft spot was operating cash generation, which declined 11% to £863 million.

Bupa attributed the reduction to the timing of claims payments, tax instalments and other working capital movements, which offset the benefit of higher profitability. The group still described cash generation as strong.

The cash flow statement showed £1.04 billion generated from operations before tax and restricted cash movements. After £171 million of tax payments, net operating cash flow was £863 million.

Cash flow therefore remains substantial, but investors should monitor whether the year-on-year decline proves temporary or continues into the full-year results.

Investment supports growth but creates execution risks

Bupa continues to expand its healthcare provision network. It added 95 sites over the last year, including 23 during the latest six months, and now operates 919 dental centres, 538 clinics and health centres, and 28 hospitals.

The proposed acquisition of Partnered Health Group in Australia remains subject to regulatory approval. Following the acquisition announcement, Partnered Health reported a cyber security incident affecting some of its systems. Bupa said the transaction had not completed, no systems had been integrated and no Bupa-held customer or employee data was affected.

Digital investment is also continuing. Registered users of Bupa's Blua digital healthcare service reached almost nine million, while the group has expanded its mental health and genomics capabilities.

These initiatives could support future customer growth, but acquisitions, site expansion and technology spending also carry integration, cost and execution risks.

What investors should watch next

The results contain plenty of positives: double-digit revenue and profit growth, improving insurance economics, lower leverage and a Solvency II ratio above Bupa's stated working range.

The points requiring attention are the decline in operating cash flow, investment-related pressure within UK Health Services and exposure to regulatory change across Bupa's international markets. The group also highlighted geopolitical uncertainty, inflation, workforce availability and information security as continuing risks.

Bupa did not provide a numerical full-year profit forecast. Management said the group was encouraged by its momentum and believed its diversified business model and financial strength left it well placed to navigate the uncertain environment.

For creditors, the half-year statement presents a business growing profit while strengthening its capital position. The next test is whether Bupa can maintain those margins and convert more of its rising earnings into cash during the second half.